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Profoundly Reduced Neovascularization Capacity of Bone
Marrow Mononuclear Cells Derived From Patients With
Chronic Ischemic Heart Disease
Christopher Heeschen, MD*; Ralf Lehmann, MD*; Jörg Honold, MD; Birgit Assmus, MD;
Alexandra Aicher, MD; Dirk H. Walter, MD; Hans Martin, MD;
Andreas M. Zeiher, MD; Stefanie Dimmeler, PhD
Background—Cell therapy with bone marrow–derived stem/progenitor cells is a novel option for improving neovascu-
larization and cardiac function in ischemic heart disease. Circulating endothelial progenitor cells in patients with
coronary heart disease are impaired with respect to number and functional activity. However, whether this impairment
also extends to bone marrow–derived mononuclear cells (BM-MNCs) in patients with chronic ischemic cardiomyopathy
(ICMP) is unclear.
Methods and Results—BM-MNCs were isolated from bone marrow aspirates in 18 patients with ICMP (ejection fraction,
3811%) and 8 healthy control subjects (controls). The number of hematopoietic stem/progenitor cells (CD34/
CD133), CD49d (VLA-4) cells, and CXCR4 cells did not differ between the 2 groups. However, the colony-forming
capacity of BM-MNCs from patients with ICMP was significantly lower compared with BM-MNCs from healthy
controls (37.325.0 versus 113.870.4 granulocyte-macrophage colony-forming units; P0.009). Likewise, the
migratory response to stromal cell–derived factor 1 (SDF-1) and vascular endothelial growth factor (VEGF) was
significantly reduced in BM-MNCs derived from patients with ICMP compared with BM-MNCs from healthy controls
(SDF-1, 46.326.2 versus 108.640.4 cells/microscopic field, P0.001; VEGF, 3424.2 versus 54.829.3 cells/
microscopic field, P0.027). To assess the in vivo relevance of these findings, we tested the functional activity of
BM-MNCs to improve neovascularization in a hindlimb animal model using nude mice. Two weeks after ligation of the
femoral artery and intravenous injection of 5105 BM-MNCs, laser Doppler–derived relative limb blood flow in mice
treated with BM-MNCs from patients with ICMP was significantly lower compared with mice treated with BM-MNCs
from healthy controls (0.450.14 versus 0.680.15; P0.001). The in vivo neovascularization capacity of BM-MNCs
closely correlated with the in vitro assessment of SDF-1–induced migration (r0.78; P0.001) and colony-forming
capacity (r0.74; P0.001).
Conclusions—BM-MNCs isolated from patients with ICMP have a significantly reduced migratory and colony-forming
activity in vitro and a reduced neovascularization capacity in vivo despite similar content of hematopoietic stem cells.
This functional impairment of BM-MNCs from patients with ICMP may limit their therapeutic potential for clinical cell
therapy. (Circulation. 2004;109:1615-1622.)
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Despite improved pharmacological therapy, congestiveheart failure remains the leading cause of cardiovascular
mortality in the United States and Europe.1 Cell therapy is a
promising novel option to improve vascularization or cardiac
regeneration.2 In animal models, bone marrow–derived stem/
progenitor cell infusion improves cardiac function and neo-
vascularization after myocardial infarction.3–6 The bone mar-
row contains different types of stem cells. Hematopoietic
stem/progenitor cells, defined as CD34 cells in humans or
c-kit/sca-1 cells in mice, are incorporated into newly
formed blood vessels, augment neovascularization, and were
shown to give rise to cardiomyocytes.3,5 Moreover, human
bone marrow–derived mesenchymal cells or isolated side
population cells engraft and differentiate to a cardiomyocyte
phenotype in murine hearts.7,8 Finally, adult circulating en-
dothelial progenitor cells can give rise to new blood vessels
and differentiate to cardiac myocytes in vitro.9,10 Recent
clinical studies provide further evidence for a promising
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improvement of cardiac function after intracoronary infusion
of bone marrow–derived cells in patients with acute myocar-
dial infarction.11–13
Previous studies demonstrate that risk factors for coronary
artery disease correlate with a reduced number and functional
activity of circulating endothelial progenitor cells.14 More-
over, diabetic patients showed impaired proangiogenic and
colony-forming activity of circulating endothelial progenitor
cells.15,16 The reduction of circulating progenitor cells in the
peripheral blood may have different reasons, including induc-
tion of cell death, enhanced homing, or inhibition of differ-
entiation. Alternatively, the reduced number and functional
activity could be a result of an impaired mobilization of
progenitor cells from the bone marrow. Because the regula-
tion of stem/progenitor cells in the bone marrow of patients
with heart disease has not yet been elucidated, we determined
the number and the functional activity of stem/progenitor
cells from bone marrow aspirates isolated from patients with
chronic ischemic cardiomyopathy (ICMP).
Methods
Study Population
We collected bone marrow aspirates from a total of 8 healthy control
subjects (controls) and 18 patients with stable coronary heart disease
and a history of myocardial infarction at between 18 and 75 years of
age. Patients had to have regional wall motion abnormalities, a patent
native vessel, coronary artery bypass graft, or collateral artery.
Because myocardial ischemia is known to mobilize bone marrow–
derived progenitor cells, patients with evidence for inducible or
resting myocardial ischemia during the previous 4 weeks were
excluded. Further exclusion criteria were the presence of active or
chronic infection, operations or trauma within the previous 2 months,
evidence for malignant diseases, active gastrointestinal bleeding,
uncontrollable hypertension 160/100 mm Hg, stroke within the
previous 2 years, arteriovenous aneurysm, renal or hepatic insuffi-
ciency, thrombocytopenia with platelet counts 100 000/L, ane-
mia with hemoglobin 8.5 g/dL, mental retardation, enrollment in
another clinical trial, or unwillingness to participate. We also
excluded pregnant and premenopausal women. The ethics review
board of the Hospital of the Johann Wolfgang Goethe University of
Frankfurt, Germany, approved the protocol, and the study was
conducted in accordance with the Declaration of Helsinki. Written
informed consent was obtained from each patient.
Bone Marrow Mononuclear Cells
A total of 50 mL of bone marrow aspirate was obtained from each
participant. Bone marrow–derived mononuclear cells (BM-MNCs)
were isolated by density gradient centrifugation. After 2 washing
steps, cells were resuspended in 10 mL X-vivo 10 medium (Cam-
brex). The cell suspension consists of heterogeneous cell popula-
tions, including hematopoietic progenitor cells.
Flow Cytometry Analysis of BM-MNCs
For the identification of hematopoietic and mesenchymal stem/
progenitor cell populations, we used directly conjugated antibodies
against human CD45 (Becton Dickinson), CD34 (FITC-labeled; BD
Pharmingen), CD133 (APC-labeled; BD Pharmingen), CD14 (FITC-
labeled; BD Pharmingen), CXCR4 (APC-labeled, BD Pharmingen),
and CD49d (APC-labeled; BD Pharmingen). The lineage panel was
obtained from BD Pharmingen (containing FITC-labeled CD3,
CD14, CD16, CD19, CD20, and CD56) and was completed by also
using directly FITC-conjugated antibodies against CD15 and glyco-
phorin A (both from BD Pharmingen).
Colony-Forming Unit Assay
BM-MNCs (1105 per dish) were seeded in methylcellulose plates
(Methocult GF H4535 including stem cell factor, granulocyte col-
ony–stimulating factor, granulocyte-macrophage colony–stimulating
factor, interleukin-3, and interleukin-6; CellSystems). Plates were
studied under phase-contrast microscopy, and granulocyte-macro-
phage colony–forming units (CFU-GM; colonies 50 cells) were
counted after 14 days of incubation by 2 independent investigators.
Assessment of Migratory Capacity of BM-MNCs
A total of 1106 BM-MNCs were resuspended in 250 L X-Vivo
and placed in the upper chamber of a modified Boyden chamber
filled with Matrigel (BioCoat invasion assay, 8-m pore size, Becton
Dickinson Labware). Then, the chamber was placed in a 24-well
culture dish containing 500 L endothelial basal medium supple-
mented with 10% fetal calf serum and singlequots. For some
experiments, 50 ng/mL vascular endothelial growth factor (VEGF)
or 100 ng/mL stromal cell–derived factor 1 (SDF-1) was added.
After 24 hours of incubation at 37°C, transmigrated cells were
counted by 2 independent investigators.
Hindlimb Ischemia Model
The neovascularization capacity of BM-MNCs was investigated in a
murine model of hindlimb ischemia by use of 8- to 10-week-old
athymic NMRI nude mice (Jackson Laboratory, Bar Harbor, Me)
weighing 18 to 22 g. The proximal portion of the femoral artery
including the superficial and the deep branch as well as the distal
portion of the saphenous artery were ligated with 7-0 silk suture. All
arterial branches between the ligation were obliterated with an
electrical coagulator. The overlying skin was closed with 3 surgical
staples. After 24 hours, BM-MNCs were injected intravenously.
Limb Perfusion Measurements
After 2 weeks, we measured ischemic (right)/normal (left) limb
blood flow ratio with a laser Doppler blood flowmeter (Laser
Doppler Perfusion Imager System, moorLDI-Mark 2, Moor Instru-
ments). Before scanning was initiated, mice were placed on a heating
pad at 37°C to minimize variations in temperature. After two
recordings of laser Doppler color images, the average perfusions of
the ischemic and nonischemic limb were calculated on the basis of
colored histogram pixels. To minimize variables including ambient
light and temperature, calculated perfusion was expressed as the ratio
of ischemic to nonischemic hindlimb perfusion.
Histological Evaluation
Tissue vascularization was determined in 5-m frozen sections of
the adductor and semimembranous muscles from the ischemic and
the nonischemic limbs. Endothelial cells were stained with FITC-
labeled monoclonal antibody directed against CD146 (Chemicon).
Capillary density is expressed as number of capillaries per myocyte.
Human BM-MNCs were identified by costaining with HLA-A,B,C-
APC–labeled antibodies (BD Pharmingen) and CD146-FITC–la-
beled antibodies.
Statistical Analysis
If not stated otherwise, results for continuous variables are expressed
as meanSD. Comparisons between groups were analyzed by t test
(2-sided) or ANOVA for experiments with 2 subgroups. Post hoc
range tests and pairwise multiple comparisons were performed with
the t test (2-sided) with Bonferroni adjustment. Comparison of
categorical variables was generated by the Pearson 2 test. After
blind assessment of the in vitro characteristics of the BM-MNCs, test
results were merged with the results from the in vivo studies. To
identify in vitro determinants of BM-MNCs for their in vivo
neovascularization capacity, a multivariate linear regression analysis
was performed. Probability values 0.05 were considered statisti-
cally significant. All analyses were performed with SPSS 11.5
software.
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Results
The characteristics and the functional activity of BM-MNCs
were investigated in bone marrow aspirates from 18 patients
with ICMP and 8 healthy controls. The baseline characteris-
tics of the study population are depicted in Table 1.
Number and Migratory Potential of Bone
Marrow Cells
To investigate whether the number of stem/progenitor cells
is reduced in BM-MNCs of patients with ICMP relative to
healthy controls, we determined the number of hematopoi-
etic stem/progenitor cells characterized by the expression
of the marker protein CD34. The number of CD34/CD45
BM-MNCs was similar in both healthy controls and
patients with ICMP (n8 healthy controls; n18 patients
with ICMP) (Figure 1a). Moreover, the more immature
subset of hematopoietic progenitor cells defined as
CD133/CD34 cells and uncommitted lineage-/CD34
cells, respectively, did not differ between BM-MNCs from
patients with ICMP and BM-MNCs from healthy controls.
Likewise, mesenchymal stem cells, which were defined by
the absence of staining for CD14, CD34, and CD45, were
similar in the 2 groups. Mesenchymal stem cells represent-
ed 1.904.75% of BM-MNCs for patients with ICMP,
compared with 1.081.36% of BM-MNCs for healthy
controls (P0.51).
The functional activity of stem/progenitor cells in bone
marrow aspirates was further determined by measuring the
colony-forming activity and migration. Interestingly, BM-
MNCs from patients with ICMP showed a significantly
reduced number of colony-forming units compared with
BM-MNCs from healthy controls (37.325.0 CFU-GM
per dish versus 113.870.4 CFU-GM per dish; P0.009)
(Figure 1b). The migratory response to SDF-1 and VEGF was
also significantly reduced in BM-MNCs derived from patients
with ICMP compared with BM-MNCs from healthy controls
(VEGF, 34 00024 200 versus 54 80029 300 migrated cells,
P0.027; SDF-1, 46 30026 200 versus 108 60040 400 mi-
grated cells, P0.001) (Figure 1c). The colony-forming capacity
closely correlated with the migratory response to SDF-1
(r0.65; P0.001) but not with the migratory response to
VEGF (r0.21; P0.34).
CXCR4 is the receptor for SDF-1, which also plays a crucial
role for basal and VEGF-induced cell migration. To analyze
whether a dysregulated expression of the CXCR4 receptor
accounts for the impaired migratory response, we determined
CXCR4 surface expression by flow cytometry. The proportion
of CXCR4 lymphocytes (healthy controls, 16.663.96% of
lymphocytes versus ICMP, 14.334.66%; P0.57) and
CXCR4/CD34 lymphocytes (healthy controls, 0.260.19%
versus ICMP, 0.330.45%; P0.62) was similar for both
groups. Furthermore, we determined the extent of CXCR4
expression as the geometric mean of the logarithmic fluores-
cence (mean log fluor). The expression of CXCR4 did not differ
between BM-MNCs from healthy controls and BM-MNCs from
patients with ICMP (healthy, 21.4714.64 arbitrary units for
mean log fluor versus ICMP, 30.1223.52), even when sub-
populations (eg, CD34/CXCR4) were analyzed (data not
shown). Finally, expression of the integrin CD49d was not
different in BM-MNCs from patients with ICMP compared with
BM-MNCs from healthy controls (healthy controls, 6.664.72
versus ICMP, 5.293.11).





Age, y 59.413.4 32.14.6 0.001
Male sex, % 88.9 87.5 0.65
Hypertension, % 57 0 0.001
Hypercholesterolemia, % 70 25 0.03
Diabetes, % 17 0 0.001
Smoking, % 82.4 37.5 0.001
Family history for CHD, % 52.9 25.0 0.21
CAD (1/2/3-vessel disease), % 17.6/52.9/29.5 NA   
History of CAD, % 100 NA   
Infarct territory (anterior/inferior), % 65/35 NA   
Ejection fraction, % 37.811.1 62.63.1 0.001
Medication on discharge, %
Aspirin 100 0   
Clopidogrel 100 0   
ACE inhibitor 100 0   
-Blocker 100 0   
Statin 100 0   
C-reactive protein, mg/L 3.02.5 2.91.7 0.51
White blood cell count, 103/L 7.93.7 6.82.9 0.85
CHD indicates coronary heart disease; CAD, coronary artery disease; and NA, not applicable.
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Effect of Bone Marrow Cells on
Neovascularization After Hindlimb Ischemia
After induction of hindlimb ischemia in nude mice, BM-
MNCs from healthy controls were injected intravenously
(5104, 5105, or 5106 cells/mouse; n5 per group). After
2 weeks, the effect of cell therapy on neovascularization was
assessed by laser Doppler imaging. In accordance with
previous studies, BM-MNCs from healthy controls signifi-
cantly improved neovascularization (Figure 2a). The maximal
therapeutic effect with BM-MNCs derived from healthy
controls was achieved at a concentration of 5105 cells/
mouse (data not shown). Therefore, this dose was used for
comparison with BM-MNCs derived from patients with
ICMP.
Animals treated with 5105 BM-MNCs from patients with
ICMP showed a significantly reduced improvement of neo-
vascularization compared with 5105 BM-MNCs from
healthy controls (0.450.14 versus 0.680.15; P0.001;
n8 per group) (Figure 2a). Consistently, histological assess-
ment of the skeletal muscles revealed that BM-MNCs from
healthy controls more efficiently stimulated tissue neovascu-
larization. Capillary density was significantly higher in mice
treated with BM-MNCs from healthy controls compared with
mice treated with BM-MNCs from patients with ICMP
(18588% versus 11631% of control, P0.01; n6 per
group). Moreover, we determined the incorporation of BM-
MNCs into the capillaries by immunostaining of the tissue
sections using antibodies directed against human HLA and
the panendothelial marker CD146. The number of human
cells, which coexpress endothelial marker proteins, was
significantly reduced when BM-MNCs from patients with
ICMP were infused compared with BM-MNCs from healthy
controls (Figure 2b). To also assess the homing of human
BM-MNCs into the ischemic tissue, we analyzed sections at
an earlier time point (7 days after ischemia). Again, the
number of human HLA-positive cells was significantly lower
when BM-MNCs from patients with ICMP were infused
(2.72.3 versus 7.54.0 cells per high-power field; n9
sections per group; P0.01). These data suggest that BM-
MNCs from patients with ICMP suffer from both a marked
impairment in their capacity to home to sites of ischemia and
in their ability to incorporate and differentiate into prolifer-
ating vascular structures.
Independent Predictors for the Functional Activity
of BM-MNCs
SDF-1–induced migration but not basal migration (r0.38;
P0.061) or VEGF-induced migration (r0.35; P0.078)
correlated with the functional improvement of neovascular-
ization in the hindlimb ischemia model (r0.78; P0.001)
(Figure 3a). The colony-forming activity of the BM-MNCs
was also significantly associated with the neovascularization
capacity of the cells (r0.74; P0.001) (Figure 3b). Several
clinical baseline characteristics of the patients were also
associated with the therapeutic effect of the BM-MNCs in the
murine model of hindlimb ischemia (Table 2, left column),
but all variables except for SDF-1–induced migration lost
their level of statistical significance if the analysis was
restricted to patients with ICMP (Table 2, middle column).
To identify independent predictors for the functional ac-
tivity of BM-MNCs, we performed a multivariate linear
regression analysis including baseline characteristics (with
P0.10 necessary to enter a variable into the model). As
depicted in Table 2 (right column), the migratory capacity of
the BM-MNCs remained the only independent predictor of
the neovascularization capacity as assessed in the model
of hindlimb ischemia. The only other independent predictor
was the colony-forming capacity, although the association
fell short of achieving statistical significance.
Figure 1. A, Flow cytometry analysis for stem/progenitor mark-
ers in BM-MNCs from healthy controls and patients with stable
ischemic cardiomyopathy. No significant differences were
observed between the 2 groups. B, Functional activity of
BM-MNCs from healthy controls and patients with stable ische-
mic cardiomyopathy. Number of colony-forming units per 5105
BM-MNCs was determined after 14 days. Migratory capacity of
BM-MNCs in response to SDF-1 and VEGF was assessed using
BioCoat invasion assay. *P0.01 vs healthy controls.
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Discussion
The data of the present study demonstrate that mononuclear
cells isolated from the bone marrow of patients with ischemic
cardiomyopathy have a significantly reduced activity for
promoting neovascularization in nude mice after induction of
hindlimb ischemia. BM-MNCs have been used in first clini-
cal trials to improve cardiac regeneration in patients with
acute myocardial infarction12,13 and in patients with chronic
ischemic heart disease.19,20 The most potent subpopulation(s)
within the bone marrow, which is capable of improving
neovascularization and/or cardiac regeneration, has not been
clearly defined to date. Several experimental studies suggest
that most likely, multiple distinct cell populations of the
BM-MNC fraction are capable of contributing to vessel
formation and differentiating into cardiac myocytes. Impor-
tantly, in the present study, we did not observe any differ-
ences in the number of hematopoietic stem/progenitor cells in
the bone marrow. In the absence of specific markers for
mesenchymal stem cells, we used a negative selection for the
identification of mesenchymal stem cells as previously de-
scribed.21 However, the number of mesenchymal stem cells,
defined by negative staining for CD14, CD45, and CD34, was
also similar in patients with ICMP and healthy controls. On
the basis of these data, it is tempting to speculate that the
reduced number of circulating progenitor cells in patients
with ischemic heart disease14 is not related to a reduced
number of stem/progenitor cells in the bone marrow rather
than to an impaired mobilization from the bone marrow.
Indeed, lack of endothelium-derived nitric oxide, which is
characteristic for patients with coronary artery disease, re-
sulted in a defective mobilization of stem/progenitor cells
from the bone marrow in mice.22
Although we did not observe differences in the number of
stem/progenitor cells in the bone marrow of patients with
ICMP, the functional capacity of BM-MNCs as determined
by their colony-forming activity and their migratory response
to SDF-1 was significantly reduced in BM-MNCs isolated
from these patients. Intriguingly, the SDF-1–induced migra-
tion of the BM-MNCs and the colony-forming activity
significantly correlated with the functional activity in vivo
(Figure 3, a and b). Like their impaired migratory response to
SDF-1 and their reduced colony-forming activity in vitro,
injection of these BM-MNCs from patients with ICMP into
mice with limb ischemia showed a significantly reduced
ability to rescue limb perfusion after unilateral ligation of the
femoral artery. We therefore conclude that the reduced
functional activity rather than a decrease in a distinct stem/
progenitor cell population is limiting the neovascularization
Figure 2. Improvement of postnatal neo-
vascularization by intravenous injection
of BM-MNCs in a murine model of hind-
limb ischemia. a, Laser Doppler–derived
relative blood flow in mice 2 weeks after
induction of hindlimb ischemia.
Untreated animals served as a negative
control. Other animals received 5104
BM-MNCs derived from healthy controls
and patients with stable ischemic cardio-
myopathy, respectively. Representative
laser Doppler scans for 3 groups are
depicted. Arrows indicate ischemic and
nonischemic limb. Perfusion signal is
subdivided into 8 different intervals, each
displayed as a separate color. Low or no
perfusion is displayed as dark blue; high-
est perfusion interval is displayed as
white. b, Incorporation of human
BM-MNCs into vascular structures of
ischemic hindlimbs was assessed on day
14 after ligation of femoral arteries.
Incorporated human BM-MNCs were
identified by costaining for panendotheli-
al marker CD146 and anti-human HLA.
*P0.01 vs untreated; **P0.01 vs
healthy controls.
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potential of BM-MNCs from patients with ICMP. However,
we cannot rule out that the number of, for instance, side
population cells or other not yet identified potent cell types
may also be dysregulated in bone marrow of patients with
ICMP. More studies are warranted for the identification of the
specific cell type that is actually responsible for promoting
neovascularization.
Migration is essential for stem/progenitor cells to invade
the ischemic tissue. SDF-1 and VEGF are both profoundly
upregulated in hypoxic tissue23,24 and may thus represent
physiologically relevant chemoattractants for the recruitment
of circulating progenitor cells to sites of ischemia. Indeed,
intramuscular injection of the chemoattractant chemokine
SDF-1 has recently been shown to increase the number of
incorporated endothelial progenitor cells and to improve
neovascularization in vivo.25 Thus, the migratory response
toward SDF-1 may indeed play a crucial role for integration
of progenitor cells in ischemic tissue. The exact mechanism
underlying the impaired migratory response toward SDF-1 is
unclear. It is reasonable to hypothesize that a downregulation
of the receptor for SDF-1, CXCR4, may play a crucial role.
However, our data indicate that the surface expression of
CXCR4 in all studied cell populations does not differ be-
tween BM-MNCs from healthy controls and BM-MNCs from
patients with ICMP. Therefore, alterations of intracellular
pathways involved in the SDF-1–induced migration are more
likely and deserve further investigation. In addition, we did
not find a difference in the expression of CD49d (VLA-4), an
important integrin on stem/progenitor cells mediating their
interaction with endothelial cells via vascular cell adhesion
molecule-1.
From our study population, it is difficult to conclude which
may be the most important risk factor driving the functional
differences in stem/progenitor cells between healthy controls
and patients with ICMP. Patients with ICMP differed from
healthy controls with respect to age, cardiovascular risk
factors, presence of coronary heart disease, and left ventric-
ular function. The extensive self-renewal capacity of hema-
topoietic stem cells implies that this cell population may not
age and thus may provide undiminished replenishment of
blood cells throughout the lifespan of an organism. In support
of this idea, steady-state hematopoietic function is generally
maintained in aged mice and humans.26 When bone marrow
from old mice is transplanted into irradiated young animals,
so that the old bone marrow cells compete with young cells
during replacement of the host’s lymphohematopoietic tis-
sues, old hematopoietic stem cells are not at a competitive
disadvantage. However, more old than young hematopoietic
stem cells are necessary to reconstitute the bone marrow of a
recipient, most likely because of a reduced ability to home to
and seed the bone marrow.27 In our study population, the
number of hematopoietic stem cells in the bone marrow
showed no association with age. However, by univariate
analysis, the functional capacity of the BM-MNCs as as-
sessed by their in vivo neovascularization capacity showed a
trend toward a reduction with age (P0.06). A similar
correlation was observed for age and the in vitro assessment
of SDF-1–induced migration (P0.03). In a multivariate
model, however, other baseline characteristics were overrid-
ing this effect of age on the in vivo neovascularization
capacity of the BM-MNCs (Table 2). These data suggest that
ischemic heart disease and/or the presence of cardiovascular
risk factors contribute significantly to the functional impair-
ment of BM-MNCs in patients with ICMP. It is important to
note, however, that the disparity in the baseline characteris-
tics between the 2 patient groups limits the conclusions that
can be drawn from the present study. Although it is reason-
able to conclude that patients with ICMP have functionally
impaired stem/progenitor cells with respect to their neovas-
cularization capacity, the present study population of patients
with ICMP itself is too homogeneous regarding left ventric-
ular pump function, number of risk factors, and age to more
definitively demonstrate which factor is indeed responsible
for the functional impairment of BM-MNCs from patients
with ICMP. Future studies including patients with normal left
ventricular pump function and/or patients with impaired left
Figure 3. Correlation between functional activity of BM-MNCs in
vivo as assessed by laser Doppler imaging and their in vitro cell
characteristics. a, Correlation between neovascularization
capacity of BM-MNCs and their migratory response to SDF-1 in
vitro. b, Correlation between neovascularization capacity of
BM-MNCs and their colony-forming capacity in vitro (n26).
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ventricular function caused by dilated cardiomyopathy who
lack risk factors for coronary heart disease will be needed to
address this question.
Stem and progenitor cells may be involved not only in
postnatal neovascularization but also in atherogenesis. A
recent experimental study supports this novel concept that
atherosclerosis progression is related to obsolescence of
endogenous progenitor cells that normally repair and rejuve-
nate the arteries.28 Specifically, Rauscher et al28 demonstrated
that chronic treatment with bone marrow–derived progenitor
cells from young nonatherosclerotic apolipoprotein E–defi-
cient (ApoE/) mice prevents atherosclerosis progression in
ApoE/ recipients despite persistent hypercholesterolemia.
In contrast, treatment with bone marrow cells from older
ApoE/ mice with atherosclerosis is much less effective,
suggesting that progressive progenitor cell deficits in older
animals may contribute to the development of atherosclerosis.
The data of the present study support this novel concept of
progressive stem/progenitor cell deficit in patients with is-
chemic heart disease. Mechanistically, however, from our
data it appears more likely that this deficit is related to
stem/progenitor cell dysfunction rather than stem/progenitor
cell exhaustion.
The functional impairment of BM-MNCs from patients
with ICMP may also limit their therapeutic potential for
clinical cell therapy, especially when using an intravascular
route of administration, which requires the progenitor cells to
extravasate against a chemoattractant gradient to invade and
home to ischemic tissue. Monitoring the migratory and
colony-forming activity of stem/progenitor cells before cell
therapy may serve as a surrogate test for identifying patients
who may derive greater benefit from cell therapy. Indeed, a
recent subanalysis of the TOPCARE-AMI trial revealed that
the migratory capacity of the infused cells determines the
functional improvement of the treated patients.11 Conversely,
a recent experimental study suggests that fully functional
bone marrow– derived endothelial progenitor cells from
healthy donor mice restore the senescent host cardiac angio-
genesis in a murine model of impaired neovascularization.29
Thus, it is tempting to speculate that pharmacological or
genetic manipulation of the functionally impaired BM-MNCs
before reinfusion may improve their functional activity and
subsequently may improve the patients’ therapeutic benefit
from cell therapy.
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